NEW YORK, June 4, 2010 (GLOBE NEWSWIRE) -- Veteran business journalist Jill Bennett joins Alan Shaw, Ph.D., President and Chief Executive Officer Codexis, Inc., (Nasdaq:CDXS) to discuss the company's industry, strategy, financials and positioning.
Click here to view video:
http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=42056&k=88C5215C3BBFD1F231775F2EC6B5E20B
Alan Shaw, Ph.D., has served as President of Codexis since its inception and Chief Executive Officer since 2002. As our President and Chief Executive Officer, Mr. Shaw brings in-depth understanding of our day-to-day operations to our board of directors, of which he has been a member since 2002. Prior to Codexis, Dr. Shaw was Head of New Business Development for Clariant and Managing Director for Lancaster Synthesis and prior to Clariant's acquisition of BTP plc, Chief Operating Officer of Archimica, the pharmaceutical chemicals division of BTP plc. From 1994 to 1999, he was with Chiroscience Group plc, most recently as Managing Director of the pharmaceutical services unit, Chirotech Technology Limited, and a member of the board of directors of Chiroscience Ltd. Earlier in his career, Dr. Shaw held various scientific and management positions for over 15 years at Imperial Chemical Industries PLC (ICI)/Zeneca. Dr. Shaw serves on the boards of directors of CO2 Solution Inc. and BIO, the biotechnology industry trade association, and is chair of the BIO Industrial and Environmental Section. He holds a B.S. in chemistry from Teesside University, England and a Ph.D. in chemistry from the University of Durham, England. Dr. Shaw is a Fellow of the Royal Society of Chemistry (FRSC, C.Chem.) and the Chartered Institute of Marketing (FCIM, Chartered Marketer).
About Codexis, Inc.:
Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration with Royal Dutch Shell. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.
The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839